tetano
Editor, Senior Moderator
Vaccine. 2014 Apr 22. pii: S0264-410X(14)00515-5. doi: 10.1016/j.vaccine.2014.04.013. [Epub ahead of print]
The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012.
Turner N1, Pierse N2, Bissielo A3, Huang QS4, Baker MG5, Widdowson MA6, Kelly H7; on behalf of the SHIVERS investigation team.
Author information
Abstract
BACKGROUND:
Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ).
METHODS:
A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38?C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season.
RESULTS:
The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39% (95% CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59% (95% CI 26;77) in patients aged 45-64 years but only 8% (-78;53) in those aged 65 years and above.
CONCLUSION:
Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.
Copyright ? 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Immunisation, Influenza vaccine, Vaccination, Vaccine effectiveness
PMID:
24768730
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24768730
The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012.
Turner N1, Pierse N2, Bissielo A3, Huang QS4, Baker MG5, Widdowson MA6, Kelly H7; on behalf of the SHIVERS investigation team.
Author information
Abstract
BACKGROUND:
Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ).
METHODS:
A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38?C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season.
RESULTS:
The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39% (95% CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59% (95% CI 26;77) in patients aged 45-64 years but only 8% (-78;53) in those aged 65 years and above.
CONCLUSION:
Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.
Copyright ? 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Immunisation, Influenza vaccine, Vaccination, Vaccine effectiveness
PMID:
24768730
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24768730